mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

被引:321
作者
Fraenkel, Merav [1 ]
Ketzinel-Gilad, Mali [1 ]
Ariav, Yafa [1 ]
Pappo, Orit [2 ]
Karaca, Melis [3 ]
Castel, Julien [3 ]
Berthault, Marie-France [3 ]
Magnan, Christophe [3 ]
Cerasi, Erol [1 ]
Kaiser, Nurit [1 ]
Leibowitz, Gil [1 ]
机构
[1] Hadassah Hebrew Univ, Med Ctr, Dept Med, Endocrinol & Metab Serv, IL-91120 Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
[3] Univ Paris, CNRS, UMR, Lab Physiopathol Nutr, F-75252 Paris, France
关键词
D O I
10.2337/db07-0922
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Mammalian target of rapamycin (mTOR) and its downstream target S6 kinase 1 (S6K1) mediate nutrient-induced insulin resistance by downregulating insulin receptor substrate proteins with subsequent reduced Akt phosphorylation. Therefore, mTOR/S6K1 inhibition could become a therapeutic strategy in insulin-resistant states, including type 2 diabetes. We tested this hypothesis in the Psammomys obesus (P. obesus) model of nutrition-dependent type 2 diabetes, using the mTOR inhibitor rapamycin. RESEARCH DESIGN AND METHODS - Normoglycemic and diabetic P. obesus were treated with 0.2 mg.kg(-1).day(-1) i.p. rapamycin or vehicle, and the effects on insulin signaling in muscle, liver and islets, and on different metabolic parameters were analyzed. RESULTS - Unexpectedly, rapamycin worsened hyperglycemia in diabetic P. obesus without affecting glycemia in normoglycemic controls. There was a 10-fold increase of serum insulin in diabetic P. obesus compared with controls; rapamycin completely abolished this increase. This was accompanied by weight loss and a robust increase of serum lipids and ketone bodies. Rapamycin decreased muscle insulin sensitivity paralleled by increased glycogen synthase kinase 3 beta activity. In diabetic animals, rapamycin reduced P-cell mass by 50% through increased apoptosis. Rapamycin increased the stress-responsive c-Jun NH2-terminal kinase pathway in muscle and islets, which could account for its effect on insulin resistance and P-cell apoptosis. Moreover, glucose-stimulated insulin secretion and biosynthesis were impaired in islets treated with rapamycin. CONCLUSIONS - Rapamycin induces fulminant diabetes by increasing insulin resistance and reducing P-cell function and mass. These findings emphasize the essential role of mTOR/S6K1 in orchestrating P-cell adaptation to hyperglycemia in type 2 diabetes. It is likely that treatments based on mTOR inhibition will cause exacerbation of diabetes.
引用
收藏
页码:945 / 957
页数:13
相关论文
共 51 条
  • [11] The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
    Harrington, LS
    Findlay, GM
    Gray, A
    Tolkacheva, T
    Wigfield, S
    Rebholz, H
    Barnett, J
    Leslie, NR
    Cheng, S
    Shepherd, PR
    Gout, I
    Downes, CP
    Lamb, RE
    [J]. JOURNAL OF CELL BIOLOGY, 2004, 166 (02) : 213 - 223
  • [12] Upstream and downstream of mTOR
    Hay, N
    Sonenberg, N
    [J]. GENES & DEVELOPMENT, 2004, 18 (16) : 1926 - 1945
  • [13] Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
    Hennige, AM
    Burks, DJ
    Ozcan, U
    Kulkarni, RN
    Ye, J
    Park, SM
    Schubert, M
    Fisher, TL
    Dow, MA
    Leshan, R
    Zakaria, M
    Mossa-Basha, M
    White, MF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (10) : 1521 - 1532
  • [14] A central role for JNK in obesity and insulin resistance
    Hirosumi, J
    Tuncman, G
    Chang, LF
    Görgün, CZ
    Uysal, KT
    Maeda, K
    Karin, M
    Hotamisligil, GS
    [J]. NATURE, 2002, 420 (6913) : 333 - 336
  • [15] Sustained activation of the JNK cascade and raparnycin-induced apoptosis are suppressed by p53/p21Cip1
    Huang, S
    Shu, LL
    Dilling, MB
    Easton, J
    Harwood, FC
    Ichijo, H
    Houghton, PJ
    [J]. MOLECULAR CELL, 2003, 11 (06) : 1491 - 1501
  • [16] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Hudes, Gary
    Carducci, Michael
    Tomczak, Piotr
    Dutcher, Janice
    Figlin, Robert
    Kapoor, Anil
    Staroslawska, Elzbieta
    Sosman, Jeffrey
    McDermott, David
    Bodrogi, Istvan
    Kovacevic, Zoran
    Lesovoy, Vladimir
    Schmidt-Wolf, Ingo G. H.
    Barbarash, Olga
    Gokmen, Erhan
    O'Toole, Timothy
    Lustgarten, Stephanie
    Moore, Laurence
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) : 2271 - 2281
  • [17] Psammomys obesus, a model for environment-gene interactions in type 2 diabetes
    Kaiser, N
    Nesher, R
    Donath, MY
    Fraenkel, M
    Behar, V
    Magnan, C
    Ktorza, A
    Cerasi, E
    Leibowitz, G
    [J]. DIABETES, 2005, 54 : S137 - S144
  • [18] Dynamic changes in β-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus -: Impact of glycemic control
    Kaiser, N
    Yuli, M
    Üçkaya, G
    Oprescu, AI
    Berthault, MF
    Kargar, C
    Donath, MY
    Cerasi, E
    Ktorza, A
    [J]. DIABETES, 2005, 54 (01) : 138 - 145
  • [19] MONOLAYER-CULTURE OF ADULT-RAT PANCREATIC-ISLETS ON EXTRACELLULAR-MATRIX - LONG-TERM MAINTENANCE OF DIFFERENTIATED B-CELL FUNCTION
    KAISER, N
    CORCOS, AP
    TURSINAI, A
    ARIAV, Y
    CERASI, E
    [J]. ENDOCRINOLOGY, 1988, 123 (02) : 834 - 840
  • [20] HYPERINSULINEMIA INDUCES A REVERSIBLE IMPAIRMENT IN INSULIN-RECEPTOR FUNCTION LEADING TO DIABETES IN THE SAND RAT MODEL OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    KANETY, H
    MOSHE, S
    SHAFRIR, E
    LUNENFELD, B
    KARASIK, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (05) : 1853 - 1857